An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Edgewise Therapeutics to Present at Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced that its senior management will participate in two upcoming investor conferences:
Jefferies Healthcare Conference: Presentation on June 10, 2022, at 10 am ET.
Goldman Sachs Annual Global Healthcare Conference: Fireside chat on June 15, 2022, at 4 pm PT (7 pm ET).
Both events will be webcast live and available for replay. Edgewise focuses on developing therapies for rare muscle disorders using a proprietary drug discovery platform.
Positive
None.
Negative
None.
BOULDER, Colo.--(BUSINESS WIRE)--
Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team will participate in the following upcoming investor conferences:
Jefferies Healthcare Conference Presentation:Friday, June 10, 2022, at 10 am ET
Goldman Sachs Annual Global Healthcare Conference
Fire Side Chat:Wednesday, June 15, 2022, at 4 pm PT (7 pm ET)
The presentations will be webcast live under the Edgewise events page and will be accessible for replay following the presentations. It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, Twitter and Facebook.
